# Lilly Introduces Zepbound® Single-Dose Vials, Enhancing Supply and Access for Individuals Dealing with Obesity ### Key Points: – Lilly has launched tirzepatide (Zepbound®) in single-dose vials, broadening the availability and accessibility of this treatment for adults grappling with obesity. – This initiative aims to provide more options for healthcare professionals and patients when it comes to managing obesity and its related health issues. – Zepbound® is designed to help individuals achieve their weight loss goals by targeting multiple metabolic pathways to improve glucose control, decrease body weight, and enhance cardiovascular health. ### Hot Take: Lilly’s introduction of Zepbound® in single-dose vials is a significant step towards supporting individuals facing the challenges of obesity. By expanding supply and access to this treatment, Lilly is empowering more people to take charge of their health and work towards achieving their weight loss objectives. Contact Mindful Evolution today to learn more about how we can support you in your weight loss journey through telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia. Weight loss disclaimer: Results may vary. It is essential to consult with a healthcare provider before starting any weight loss program or taking any medication.